Such randomization of patients is to be in a 1:2:2 fashion, as follows: 1.2 mg of Pemvidutide - 38 patients 1.8 mg of ...

J&J is the third medtech company to gain U.S. approval for pulsed field ablation, a new atrial fibrillation treatment seeing rapid adoption.

Company and Agency aligned on key efficacy and safety measures to be studied in Phase 3 programPivotal Phase 3 trials designed to leverage the ...